TEL AVIV, Israel, Sept. 8, 2014 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd, (Nasdaq:ORPN) a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today that in celebration of its recently completed initial public offering and NASDAQ Global Market Listing, it will ring the opening bell at the NASDAQ MarketSite in Times Square on Tuesday, September 9, 2014.
"We are excited to celebrate our recently completed IPO and listing on the NASDAQ Global Market," said Dr. Dalia Megiddo, Chief Executive Officer of BioBlast. "Trading on the world's largest global trading platform has heightened awareness of our deep commitment to advance our portfolio of drug candidates to treat rare genetic diseases."
A live webcast BioBlast's NASDAQ Opening Bell ceremony will be available at https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
About BioBlast Pharma Ltd.
BioBlast Pharma is a publicly traded, clinical-stage biotechnology company (Nasdaq:ORPN) committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Founded in 2012, the company is rapidly building a diverse portfolio of product candidates with the potential to address unmet medical need for incurable rare diseases. Our therapeutic platforms are based on deep understanding of the disease-causing biological mechanism, and can potentially offer solutions for several diseases that share the same biological pathology. For more information please visit the Company's website, www.bioblast-pharma.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward looking statements when we discuss building and advancing our portfolio of drug candidates with the potential to address unmet medical needs for incurable diseases, or that our platforms potentially offer solutions for several diseases that share the same biological pathology. Because such statements deal with future events and are based on BioBlast Pharma Ltd.'s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of BioBlast Pharma could differ materially from those described in or implied by the statements in this press release, including those discussed under the heading "Risk Factors" in BioBlast Pharma's registration statement on Form F-1 filed with the Securities and Exchange Commission ("SEC") and in any subsequent filings with the SEC. Except as otherwise required by law, BioBlast Pharma disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
CONTACT: Company Contact: Zoe Shafir +972 722 409 060 firstname.lastname@example.org U.S. Investor Contact: Michael Rice Founding Partner LifeSci Advisors, LLC email@example.com (646) 597-6979Source: BioBlast Pharma